Ignite Creation Date:
2024-05-05 @ 5:03 PM
Last Modification Date:
2024-10-26 @ 9:27 AM
Study NCT ID:
NCT00370981
Status:
COMPLETED
Last Update Posted:
2013-12-27
First Post:
2006-08-30
Brief Title:
Exploratory Study of Pagoclone in Men With Premature Ejaculation
Sponsor:
Endo Pharmaceuticals
Organization:
Endo Pharmaceuticals
Study Overview
Official Title:
A Four-arm Randomized Double-blind Parallel Placebo-controlled Exploratory Study of Pagoclone 015mg 030mg and 060mg in Men With Primary Premature Ejaculation
Status:
COMPLETED
Status Verified Date:
2007-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate pagoclone in the treatment of premature ejaculation
Detailed Description:
The primary objective of this study is to evaluate the effect of 3 dose levels of pagoclone 015 mg 030 mg and 060 mg versus placebo on intravaginal ejaculation latency time IELT male patients with primary premature ejaculation
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None